BioSpace News Archive

Fresenius Kabi announced today the immediate availability in the United States of Foscarnet Sodium Injection. Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.

ResMed, a world-leading digital health company, announced the results of a nationwide survey of 1,000 adults, which revealed that for half of Americans, stress over the past year is negatively impacting the quality of their sleep – and many are ignoring sleep challenges that could point to a larger underlying health concern.

Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outlines common COVID-19 symptoms and at-home steps that can be discussed with health care providers to reduce symptoms.

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today during the Presidential Symposium at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) announced the results from a subgroup analysis of the Phase 3 TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir), which supported the efficacy results from the overall randomized population

The American Cancer Society is a global grassroots force of nearly 2 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer.

EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund.

A novel theory recently published in the Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve stimulation (PNS) may recondition the central nervous system (CNS) to restore normal pain processing and provide long-term pain relief for patients.

Carolina Liquid Chemistries Corp. announces its value-added distributorship for Mindray North America Hematology Systems.

ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100 in advanced clinical development, announces that its partner, NeuroRx, Inc., has reported that work is underway to determine the feasibility of formulating RLF-100 as a dry powder using TFF Pharmaceuticals’ Thin-Film Freezing technology.